Loading clinical trials...
Loading clinical trials...
The Effectiveness and Tolerability of Fentanyl Matrix in Chronic Non-cancer Pain; Assessment of Patient's Pain Treatment Goal Achievement: Multicenter, Prospective, Open-label, Observational Study
The purpose of this study is to assess the effectiveness and tolerability of Fentanyl matrix in chronic non-cancer pain.
This is a multicenter, prospective (a study in which the patients are identified and then followed forward in time for the outcome of the study), open-label (all people know the identity of the intervention), observational study intended to examine the effectiveness of Fentanyl matrix through the degree of improvement of pain. Fentanyl matrix is a transdermal (through the skin) system providing continuous delivery of fentanyl for 72 hours. Fentanyl matrix will be administered to patients with chronic (prolonged) non-cancer pain under routine practice during 12 weeks. Dose will be adjusted in accordance with patient's degree of pain and treatment response in the investigator's judgment.
Age
20 - No limit years
Sex
ALL
Healthy Volunteers
No
Andong, South Korea
Busan, South Korea
Daegu, South Korea
Daejeon, South Korea
Goyang, South Korea
Incheon, South Korea
Jeonju, South Korea
Kwangiu, South Korea
Kwanju, South Korea
Seoul, South Korea
Start Date
December 1, 2011
Primary Completion Date
March 1, 2013
Completion Date
March 1, 2013
Last Updated
November 21, 2013
410
ACTUAL participants
Fentanyl matrix
DRUG
Lead Sponsor
Janssen Korea, Ltd., Korea
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06219408